What Hepatitis-Delta Means for Healthcare Practices

If you run a hepatology or primary-care operation, the news that matters is not "a new hepatitis drug got approved." It is that a disease nobody screened for — because there was nothing to offer — just became worth testing roughly 80,000 Americans for. This piece answers one question: what does hepatitis-delta actually change for the people running a healthcare practice over the next 12-36 months — which daily tasks, which costs, which staffing decisions.

For the full plain-English explanation of the disease and the approval itself, start with the hub: hepatitis-delta explained. This page is the operator's view.

The reason this is an operations story and not just a clinical one is timing. The clinical decision — whether a confirmed HDV patient should start a once-daily injection — is relatively straightforward once the patient is identified and approved. What is new and unbuilt is everything around that decision: the reflex testing that finds the patient, the prior authorization that pays for the drug, and the monitoring that the boxed warning makes mandatory. None of that infrastructure existed when there was nothing to prescribe. Practices are effectively standing up a new specialty pathway from zero, and they are doing it for a patient population most of whom do not yet know they have the disease.

Who should care

You should read on if you are a practice administrator, hepatology or gastroenterology lead, or primary-care operations manager whose panel includes hepatitis B patients, running an EHR with reflex-testing and prior-authorization workflows. The pain this touches: a new screening obligation, a specialty injectable to authorize and monitor, and the back-office load both create.

Red flags: this is not for you if (1) your panel has essentially no hepatitis B patients, so the reflex-test population is near zero, (2) you have no specialty-pharmacy or prior-auth pathway and no plan to build one, or (3) you expect this to be a clinical-only change — because the first-order impact is operational, and treating it as purely clinical is the fastest way to drown in faxes.

What changes at the task level

According to Gilead, the May 22, 2026 approval creates three new tasks that did not meaningfully exist before: reflex HDV testing on HBV-positive patients, prior authorization for a daily specialty injectable, and ongoing adherence and lab monitoring tied to a boxed warning.

The screening task is the biggest volume driver. About 80,000 Americans have HDV, roughly 4% of hepatitis B patients — and according to the Hepatitis B Foundation, that 80,000 figure at 4% prevalence is mostly undiagnosed, because until now there was no reason to look.

The good news for operations is that the at-risk population is already in your records. Because chronic HDV only occurs in people who already carry hepatitis B — HDV needs HBV to replicate, as the World Health Organization explains — every candidate for screening already has a positive HBV result somewhere in the chart. The screening task is therefore not "find new patients" but "look one field over on patients you already know." That is precisely the kind of deterministic, rule-based trigger that belongs in an automated order set rather than a clinician's memory, because relying on memory is how a positive HBV from two years ago never gets the reflex HDV test it now warrants.

Before and after, by task

What changes at the cost level

The cost is front-loaded into administration, not the drug itself. A daily subcutaneous specialty injectable, per Gilead, means specialty-pharmacy coordination, prior authorization, and monitoring labor — the document-shaped work that scales with patient count, not clinical complexity.

The screening cost is a new line item too. According to the World Health Organization, HDV affects nearly 5% — an estimated 12 million — of chronic HBV patients globally, and reflex-testing an entire HBV panel generates lab orders, result routing, and follow-up that did not exist a month ago. Practices running US Tech Automations workflows automate the reflex-test trigger so an HBV-positive result orders the HDV test without a human re-keying it, which is the difference between a screening program and a screening backlog.

Where the cost moves

What changes at the staffing level

Staffing pressure lands on the back office before it lands on clinicians. The new work — reflex orders, prior auths, monitoring schedules — is coordinator and pharmacy-tech work, not physician work. Given that, according to the Hepatitis B Foundation, about 80,000 Americans are now screening-relevant, even a single practice's share of that panel is real administrative volume.

The staffing decision is whether to hire for the new load or automate the routing first. The FDA press announcement makes the boxed-warning monitoring non-optional, so the monitoring labor is fixed — but the reflex-test ordering and prior-auth packaging are exactly the steps that automate well. The firms that operationalize this first redeploy staff to the monitoring that needs judgment and let software handle the routing.

The distinction matters because the two kinds of work scale differently. Monitoring labor scales with the number of patients on therapy and is bounded by clinical judgment — a nurse has to read the labs and make a call. Reflex-test ordering and prior-auth packaging scale with the size of the HBV panel and are almost entirely rule-based — an HBV-positive result either triggers the HDV order or it does not. Trying to staff the rule-based work with people is how practices end up with coordinators spending their days re-keying lab results and re-faxing prior auths, while the genuinely clinical monitoring goes under-resourced. The better division of labor puts software on the rule-based routing and people on the judgment, and a daily-injection drug with a boxed warning means the judgment side is where you want your scarce clinical staff focused.

Staffing decision matrix

Worked example

Consider a gastroenterology practice with 600 hepatitis B patients on its panel. Apply the Hepatitis B Foundation figure that about 4% of HBV patients also carry HDV: that implies roughly 24 undiagnosed HDV patients in a 600-patient panel, each now a candidate for the once-daily 8.5 mg injection Gilead describes, and each requiring a prior authorization. In a typical specialty stack, a positive HDV result and a started prior auth surface as a downstream status change — for example a prior_authorization.approved event in the EHR or PA platform — and the firms that operationalize hepatitis-delta first wire the HBV-positive lab result to auto-order the reflex HDV test and pre-package the PA, so 24 new cases do not become 24 manual fax chases. Given the Pharmacy Times efficacy of 48% combined response at week 48, the clinical upside is real — but only the practices that cleared the administrative path will get patients onto therapy fast enough to capture it.

Screening-volume worksheet (illustrative)

The arithmetic is illustrative, applying the ~4% HDV prevalence among HBV patients from the Hepatitis B Foundation to three panel sizes.

Each positive is a candidate for the once-daily 8.5 mg injection per Gilead, and every candidate generates a prior auth and a monitoring schedule.

Signal vs Speculation

The sourced facts: the May 22, 2026 approval; ~80,000 affected Americans at ~4% of HBV patients; the once-daily 8.5 mg dosing; the 48%-vs-2% MYR301 endpoint; the boxed warning — from Gilead, the Hepatitis B Foundation, Pharmacy Times, and the FDA. Everything below is forecast.

Our read: the next 12-36 months are a screening and authorization story, not a prescribing one. The practices that win will be the ones that turn the HBV-positive lab result into an automatic reflex HDV order and a pre-built prior-auth packet, because the clinical decision is straightforward once the patient is identified and approved. The administrative path — testing, PA, specialty pharmacy, monitoring — is the bottleneck, and it is exactly the document-shaped work that overwhelms small specialty practices. Our bet: the firms that operationalize that routing first capture disproportionate volume, and teams running US Tech Automations workflows can attach the reflex-test trigger and PA packaging to their existing stack rather than rebuilding it.

Key Takeaways

• The first HDV treatment changes practice operations more than clinical practice: screening, prior auth, and monitoring are the new tasks, anchored to the May 22, 2026 Gilead approval.

• The volume driver: ~80,000 Americans, about 4% of hepatitis B patients, per the Hepatitis B Foundation, most undiagnosed.

• The cost moves to administration — reflex labs, prior auths, specialty-pharmacy coordination, and boxed-warning monitoring.

• The win condition is automating the reflex-test order and PA packaging before the screening volume arrives.

• Clinical upside (48% response at week 48 per Pharmacy Times) only lands if the administrative path is clear.

Frequently Asked Questions

What does the first hepatitis-delta treatment change for a practice?

It creates three new operational tasks — reflex HDV testing on HBV-positive patients, prior authorization for a daily specialty injectable, and boxed-warning monitoring — none of which existed before the May 22, 2026 Gilead approval.

How many patients should we expect to screen?

Roughly 4% of your hepatitis B panel, since about 80,000 Americans — that share of HBV patients — have HDV, according to the Hepatitis B Foundation. On a 600-patient HBV panel that is about 24 candidates.

Is this a primary-care problem or a specialist problem?

Both. The reflex-test order often starts in primary care on the HBV panel, while the specialty injectable, prior auth, and monitoring sit with hepatology — per the dosing and warning detail in Gilead and the FDA.

What is the biggest operational risk?

Drowning in manual back-office work. A daily injectable with a boxed warning, per the FDA, generates prior auths and monitoring that scale with patient count; practices that re-key results and faxes by hand will fall behind.

How effective is the treatment we are authorizing?

According to Pharmacy Times, in the MYR301 trial 48% of treated patients met the week-48 combined endpoint versus 2% of controls. That clinical upside depends on getting identified patients through the administrative path quickly.

The clinical decision is the easy part; the screening and authorization path is where practices win or stall. See how reflex-test routing, prior-auth packaging, and monitoring follow-up can run as connected automations with our customer-service and operations agents. For the disease background, read hepatitis-delta explained. Related operations playbooks: referral tracking between specialists, home-health authorization re-verification, insurance eligibility verification, and routing referral requests to specialists.

Freshness note: current as of June 2026, anchored to the May 22, 2026 FDA accelerated approval of Hepcludex.